US drugmaker Orexigen Therapeutics (Nasdaq: OREX) says that medicines regulator Health Canada has completed its screening phase and accepted for review a New Drug Submission for marketing approval of Contrave (naltrexone HCl and bupropion HCl), the company’s weight management product.
The regulatory submission was filed by an affiliate of Canada’s Valeant Pharmaceuticals International (TSX: VRX). If approved, Valeant will market and distribute Contrave in Canada as part of its distributorship agreement with Orexigen, executed in August 2016.
Under the terms of the agreement, Valeant is responsible for obtaining regulatory approval and for all commercialization activity and expenses. Valeant expects to begin marketing Contrave in the first half of 2018, if regulatory approval is obtained.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze